Summit Therapeutics Inc. Stock

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate 22:57:47 19/10/2026 HKT 5-day change 1st Jan Change
15.54 USD +6.19% Intraday chart for Summit Therapeutics Inc. -9.89% -11.75%

Valuation: Summit Therapeutics Inc.

Market Cap 8.77B 11.7B 10.4B 9.64B 16.55B 1,110B 16.82B 116B 45.43B 579B 43.91B 42.98B 1,847B P/E 2026 *
-12.7x
P/E 2027 * -12.5x
Enterprise Value 8.51B 11.35B 10.09B 9.35B 16.06B 1,077B 16.31B 112B 44.07B 562B 42.6B 41.69B 1,792B EV / Sales 2026 *
2,895x
EV / Sales 2027 * 209x
Free-Float
19.13%
Yield 2026 *
-
Yield 2027 * -
09-22 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
09-15 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
09-15 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
09-10 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09-09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
08-26 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
08-26 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
08-26 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
08-26 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
08-25 Wall Street Wants Receipts Zonebourse
08-25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
08-12 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
08-12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day+6.19%
1 week-9.89%
Current month-8.72%
1 month-8.67%
3 months+14.33%
6 months-38.55%
Current year-11.75%
1 week 14.56
Extreme 14.56
16.79
1 month 14.56
Extreme 14.56
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 55 11/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Free

Controller/Auditor

100,000 0.0125%
4/6/26 Buy

Chief Executive Officer

100,000 0.0129%
4/6/26 Buy

Chief Executive Officer

100,000 0.0129%
Change 5-day change 1-year change 3-year change Capi.($)
+6.19%-9.89%-22.96%+738.86% 11.7B
+1.52%-7.16%+51.66%+67.41% 65B
+0.91%+6.48%+10.52%+78.71% 51.2B
+0.47%-0.30%+0.14%+62.16% 51.19B
-0.78%+0.87%+24.73%+41.63% 43.93B
+0.05%+5.37%+15.90%+132.70% 41.96B
+1.36%-6.90%+234.31%+522.62% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.76%+2.17%+27.91%+27.95% 22.5B
Average +1.26%-1.55%+39.82%+173.35% 38.41B
Weighted average by Cap. +0.90%-0.47%+43.01%+130.78%

Financials

2026 *2027 *
Net sales 2.94M 3.92M 3.49M 3.23M 5.55M 372M 5.64M 38.83M 15.22M 194M 14.72M 14.4M 619M 41.98M 56.01M 49.78M 46.14M 79.22M 5.32B 80.49M 555M 217M 2.77B 210M 206M 8.84B
Net income -701M -935M -831M -770M -1.32B -88.75B -1.34B -9.26B -3.63B -46.31B -3.51B -3.43B -148B -743M -991M -881M -817M -1.4B -94.07B -1.42B -9.82B -3.85B -49.09B -3.72B -3.64B -156B
Net Debt -262M -349M -311M -288M -494M -33.16B -502M -3.46B -1.36B -17.31B -1.31B -1.28B -55.17B -1.6M -2.13M -1.9M -1.76M -3.02M -202M -3.07M -21.13M -8.28M -106M -8.01M -7.84M -337M
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
19/10/26 US$15.42 +5.37% 1,529,448
16/10/26 US$14.63 -4.81% 4,331,009
15/10/26 US$15.37 +1.59% 4,733,233
14/10/26 US$15.13 -2.51% 4,661,710
13/10/26 US$15.52 -9.40% 7,131,981
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
10.97GBP
Average target price
22.65GBP
Spread / Average Target
+106.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock